+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Myocarditis Epidemiology Forecast 2025-2034

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 6092309
The global incidence of myocarditis is estimated to be around 1.5 million cases each year. The condition is reported to be caused by various infectious and noninfectious agents, with viruses considered the most common pathogen in the infectious causes.

Myocarditis Epidemiology Forecast Report Coverage

The “Myocarditis Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of myocarditis. It projects the future incidence and prevalence rates of myocarditis across various populations. The study covers age, gender, and type as major determinants of the myocarditis-affected population. The report highlights patterns in the prevalence of myocarditis over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of myocarditis in the 8 major markets.

Regions Covered

  • The United States
  • Germany
  • France
  • Italy
  • Spain
  • The United Kingdom
  • Japan
  • India

Myocarditis: Disease Overview

Myocarditis refers to the inflammation of the heart muscle or myocardium that weakens the heart muscle. It is often caused by viral infections, though it can also result from bacterial infections, autoimmune diseases, toxins, or certain medications. Some of the viruses linked to myocarditis include Coxsackievirus, adenovirus, influenza, and the COVID-19 virus. Additionally, autoimmune diseases such as lupus, rheumatoid arthritis, and sarcoidosis can cause the immune system to attack the heart muscle.

Myocarditis: Treatment Overview

Anti-inflammatory medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) are used in some cases to reduce inflammation. If myocarditis is caused by an autoimmune disorder, steroids or immunosuppressive drugs are prescribed to suppress the immune response and address inflammation. Medications like ACE inhibitors, beta-blockers, and diuretics are taken to reduce the workload on the heart if heart failure occurs due to myocarditis.

Epidemiology

The myocarditis epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for myocarditis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for myocarditis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.
  • The incidence of myocarditis is reported to be around 1.8 million cases per year globally, with rates varying significantly between 1 and over 10 cases per 100,000 people annually.
  • Studies consistently show that myocarditis occurs more frequently in men than in women, with the sex ratio ranging from 1:2 to 1:4 (female to male).
  • Some estimates suggest that 1% to 5% of people with acute viral infections may experience involvement of the myocardium. Most of these people are young and healthy, but children, pregnant women, and those with weakened immune systems are more at risk.
  • Researchers estimate that there are approximately 10 to 20 cases of myocarditis per 100,000 people worldwide each year.

Country-wise Myocarditis Epidemiology

The myocarditis epidemiology data and findings from the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of myocarditis varies between countries owing to differences in the prevalence of viral infections, vaccination coverage, access to healthcare, genetic predispositions, and environmental factors (pollution, climate, and exposure to certain chemicals or toxins), among others. In Germany, a 2023 study showed that the incidence of myocarditis among hospitalized COVID-19 patients in 2020 was about 1.28 cases per 1000 hospitalizations.

Scope of the Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of myocarditis based on several factors.
  • Myocarditis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The report helps to identify the patient population and the unmet needs of myocarditis are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

  • What are the key findings of myocarditis epidemiology in the 8 major markets?
  • What will be the total number of patients with myocarditis across the 8 major markets during the forecast period?
  • What was the country-wise prevalence of myocarditis in the 8 major markets in the historical period?
  • Which country will have the highest number of myocarditis patients during the forecast period of 2025-2034?
  • Which key factors would influence the shift in the patient population of myocarditis during the forecast period of 2025-2034?
  • What are the currently available treatments for myocarditis?
  • What are the disease risks, signs, symptoms, and unmet needs of myocarditis?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology and Assumptions
2 Executive Summary
3 Myocarditis Market Overview - 8 MM
3.1 Myocarditis Market Historical Value (2018-2024)
3.2 Myocarditis Market Forecast Value (2025-2034)
4 Myocarditis Epidemiology Overview - 8 MM
4.1 Myocarditis Epidemiology Scenario (2018-2024)
4.2 Myocarditis Epidemiology Forecast (2025-2034)
5 Disease Overview
5.1 Signs and Symptoms
5.2 Causes
5.3 Risk Factors
5.4 Guidelines and Stages
5.5 Pathophysiology
5.6 Screening and Diagnosis
5.7 Types of Myocarditis
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
7 Epidemiology Scenario and Forecast - 8 MM (218-2034)
7.1 Key Findings
7.2 Assumptions and Rationale
7.3 Diagnosed Prevalent Cases of Myocarditis
7.4 Type-Specific Cases of Myocarditis
7.5 Gender-Specific Cases of Myocarditis
7.6 Age-Specific Cases of Myocarditis
8 Epidemiology Scenario and Forecast: United States (218-2034)
8.1 Assumptions and Rationale in The United States
8.2 Diagnosed Prevalent Cases of Myocarditis in The United States
8.3 Type-Specific Cases of Myocarditis in The United States
8.4 Gender-Specific Cases of Myocarditis in The United States
8.5 Age-Specific Cases of Myocarditis in The United States
9 Epidemiology Scenario and Forecast: United Kingdom (218-2034)
9.1 Assumptions and Rationale in the United Kingdom
9.2 Diagnosed Prevalent Cases of Myocarditis in the United Kingdom
9.3 Type-Specific Cases of Myocarditis in the United Kingdom
9.4 Gender-Specific Cases of Myocarditis in the United Kingdom
9.5 Age-Specific Cases of Myocarditis in the United Kingdom
10 Epidemiology Scenario and Forecast: Germany (218-2034)
10.1 Assumptions and Rationale in Germany
10.2 Diagnosed Prevalent Cases of Myocarditis in Germany
10.3 Type-Specific Cases of Myocarditis in Germany
10.4 Gender-Specific Cases of Myocarditis in Germany
10.5 Age-Specific Cases of Myocarditis in Germany
11 Epidemiology Scenario and Forecast: France (218-2034)
11.1 Assumptions and Rationale in France
11.2 Diagnosed Prevalent Cases of Myocarditis in France
11.3 Type-Specific Cases of Myocarditis in France
11.4 Gender-Specific Cases of Myocarditis in France
11.5 Age-Specific Cases of Myocarditis in France
12 Epidemiology Scenario and Forecast: Italy (218-2034)
12.1 Assumptions and Rationale in Italy
12.2 Diagnosed Prevalent Cases of Myocarditis in Italy
12.3 Type-Specific Cases of Myocarditis in Italy
12.4 Gender-Specific Cases of Myocarditis in Italy
12.5 Age-Specific Cases of Myocarditis in Italy
13 Epidemiology Scenario and Forecast: Spain (218-2034)
13.1 Assumptions and Rationale in Spain
13.2 Diagnosed Prevalent Cases of Myocarditis in Spain
13.3 Type-Specific Cases of Myocarditis in Spain
13.4 Gender-Specific Cases of Myocarditis in Spain
13.5 Age-Specific Cases of Myocarditis in Spain
14 Epidemiology Scenario and Forecast: Japan (218-2034)
14.1 Assumptions and Rationale in Japan
14.2 Diagnosed Prevalent Cases of Myocarditis in Japan
14.3 Type-Specific Cases of Myocarditis in Japan
14.4 Gender-Specific Cases of Myocarditis in Japan
14.5 Age-Specific Cases of Myocarditis in Japan
15 Epidemiology Scenario and Forecast: India (218-2034)
15.1 Assumptions and Rationale in India
15.2 Diagnosed Prevalent Cases of Myocarditis in India
15.3 Type-Specific Cases of Myocarditis in India
15.4 Gender-Specific Cases of Myocarditis in India
15.5 Age-Specific Cases of Myocarditis in India
16 Patient Journey17 Treatment Challenges and Unmet Needs18 Key Opinion Leaders (KOL) Insights